Provexis pushes on with Crohn’s disease trial
FOOD supplement firm Provexis is pushing ahead with trials of a product for people with Crohn’s disease, an inflammation of the gastrointestinal tract.
In an update the AIM-listed company, which has its research and development facility in Liverpool, said the first 12 months of a trial looking at its efficacy and safety had yielded “no negative results” and “no safety concerns”.
A further review of the study will be delivered in the last quarter of the year and Provexis will now set up four additional trial centres.
The company has also formalised an agreement announced in February with the Dutch multinational DSM Nutritional Products to develop a new product aimed at promoting healthy blood glucose levels.
Provexis has already developed Fruitflow, a tomato-based drink which thins the blood and helps circulation. Under the agreement DSM will contribute the intellectual property while Provexis will develop a “cost effective” product, carry out clinical trials and gain the required regulatory clearances.
The company said sales of foods and drinks targeted to address heart health conditions are growing and the market is said to be worth around £5bn in the US and Europe.
